Search

Your search keyword '"n-803"' showing total 67 results
Start Over "n-803" Database Unpaywall
67 results on '"n-803"'

1. Efficiently targeting neuroblastoma (NB) by the combination of anti-ROR1 CAR NK cells and N-803 in-vitro and in-vivo of NB xenografts

Author

Chu, Yaya, primary, Nayyar, Gaurav, additional, Tian, Meijuan, additional, Lee, Dean A., additional, Ozkaynak, Mehmet F., additional, Ayala-Cuesta, Jessica, additional, Klose, Kayleigh, additional, Foley, Keira, additional, Mendelowitz, Alyssa S., additional, Luo, Wen, additional, Liao, Yanling, additional, Ayello, Janet, additional, Behbehani, Gregory K., additional, Riddell, Stanley, additional, Cripe, Tim, additional, and Cairo, Mitchell S., additional

Published
2024
Full Text
View/download PDF

3. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer

Author

Chamie, Karim, primary, Chang, Sam S., additional, Kramolowsky, Eugene V., additional, Gonzalgo, Mark L., additional, Huang, Megan, additional, Bhar, Paul, additional, Spilman, Patricia, additional, Sender, Lennie, additional, Reddy, Sandeep K., additional, and Soon-Shiong, Patrick, additional

Published
2024
Full Text
View/download PDF

4. IL15 (N-803) and IL21 (oHSV-21) Significantly Enhance ROR1 CAR NK Cells Against Pediatric Neuroblastoma

Author

Chu, Yaya, primary, Tian, Meijuan, additional, Saini, Uksha, additional, Ayala-Cuesta, Jessica, additional, Klose, Kayleigh, additional, Foley, Keira, additional, Mendelowitz, Alyssa S., additional, Cripe, Timothy P, additional, Lee, Dean Anthony, additional, Riddell, Stanley R., additional, Cassady, Kevin A., additional, and Cairo, Mitchell S., additional

Published
2024
Full Text
View/download PDF

6. Table S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

7. Figure S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

8. Figure S2 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

9. Figure S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

10. Table S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

11. Figure S2 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

12. Figure S4 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

13. Figure S4 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

14. Table S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

15. Figure S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

16. Figure S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

17. Table S2 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

18. Table S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

19. Table S2 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

20. Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

21. Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., primary, Bachanova, Veronika, primary, Bartlett, Nancy L., primary, Berrien-Elliott, Melissa M., primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foster, Mark, primary, Schappe, Timothy, primary, Kahl, Brad, primary, Mehta-Shah, Neha, primary, Cashen, Amanda F., primary, Marin, Nancy D., primary, McDaniels, Kristen, primary, Moreno, Chaz, primary, Mosior, Matthew, primary, Gao, Feng, primary, Griffith, Obi L., primary, Griffith, Malachi, primary, Wagner, Julia A., primary, Epperla, Narendranath, primary, Rock, Amy D., primary, Lee, John, primary, Petti, Allegra A., primary, Soon-Shiong, Patrick, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

23. Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.

Author

Pastor, Danielle M., primary, Redman, Jason M., additional, Floudas, Charalampos S., additional, Lamping, Elizabeth, additional, Francis, Deneise C., additional, Cordes, Lisa M., additional, Marte, Jennifer L., additional, Schlom, Jeffrey, additional, Gulley, James L., additional, and Strauss, Julius, additional

Published
2023
Full Text
View/download PDF

24. Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Author

Seery, Tara Elisabeth, primary, Nangia, Chaitali Singh, additional, Reid, Phillip D., additional, Fang, Bruno, additional, McKean, Heidi Ann, additional, Sender, Leonard S., additional, Reddy, Sandeep K., additional, and Soon-Shiong, Patrick, additional

Published
2023
Full Text
View/download PDF

25. Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803

Author

Harwood, Olivia E., primary, Balgeman, Alexis J., additional, Weaver, Abigail J., additional, Ellis-Connell, Amy L., additional, Weiler, Andrea M., additional, Erickson, Katrina N., additional, Matschke, Lea M., additional, Golfinos, Athena E., additional, Vezys, Vaiva, additional, Skinner, Pamela J., additional, Safrit, Jeffrey T., additional, Edlefsen, Paul T., additional, Reynolds, Matthew R., additional, Friedrich, Thomas C., additional, and O’Connor, Shelby L., additional

Published
2022
Full Text
View/download PDF

27. Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803

Author

Ellis-Connell, Amy L., primary, Balgeman, Alexis J., additional, Harwood, Olivia E., additional, Moriarty, Ryan V., additional, Safrit, Jeffrey T., additional, Weiler, Andrea M., additional, Friedrich, Thomas C., additional, and O’Connor, Shelby L., additional

Published
2022
Full Text
View/download PDF

29. Transient T cell expansion, activation, and proliferation in therapeutically vaccinated SIV+ macaques treated with N-803

Author

Harwood, Olivia E, primary, Balgeman, Alexis J, additional, Weaver, Abigail J, additional, Ellis-Connell, Amy L, additional, Weiler, Andrea M, additional, Erickson, Katrina N, additional, Matschke, Lea M, additional, Golfinos, Athena E, additional, Vezys, Vaiva, additional, Skinner, Pamela J, additional, Safrit, Jeffrey T, additional, Edlefsen, Paul T, additional, Reynolds, Matthew R, additional, Friedrich, Thomas C, additional, and O'Connor, Shelby L, additional

Published
2022
Full Text
View/download PDF

31. Control of SIV infection in prophylactically vaccinated, ART-naïve macaques is required for the most efficacious CD8 T cell response during treatment with the IL-15 superagonist N-803

Author

Ellis-Connell, Amy L., primary, Balgeman, Alexis J., additional, Harwood, Olivia E., additional, Moriarty, Ryan V., additional, Safrit, Jeffrey T., additional, Weiler, Andrea M., additional, Friedrich, Thomas C., additional, and O’Connor, Shelby L., additional

Published
2022
Full Text
View/download PDF

33. Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.

Author

Seery, Tara Elisabeth, primary, Nangia, Chaitali Singh, additional, McKean, Heidi Ann, additional, Bhar, Paul, additional, Sender, Leonard S., additional, Reddy, Sandeep K., additional, and Soon-Shiong, Patrick, additional

Published
2022
Full Text
View/download PDF

35. Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers

Author

Rubinstein, Mark P., primary, Williams, Cameron, additional, Mart, Caroline, additional, Beall, Jonathan, additional, MacPherson, Linda, additional, Azar, Joseph, additional, Swiderska-Syn, Marzena, additional, Manca, Paolo, additional, Gibney, Barry C., additional, Robinson, Mark D., additional, Krieg, Carsten, additional, Hill, Elizabeth G., additional, Taha, Sharif A., additional, Rock, Amy D., additional, Lee, John H., additional, Soon-Shiong, Patrick, additional, and Wrangle, John, additional

Published
2022
Full Text
View/download PDF

37. Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.

Author

Chang, Sam S., primary, Chamie, Karim, additional, Gonzalgo, Mark L., additional, Kramolowsky, Eugene V., additional, Sexton, Wade J., additional, Reddy, Sandeep K., additional, Bhar, Paul, additional, Huang, Megan, additional, and Soon-Shiong, Patrick, additional

Published
2022
Full Text
View/download PDF

38. Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Author

Seery, Tara Elisabeth, primary, Nangia, Chaitali Singh, additional, McKean, Heidi Ann, additional, Sender, Leonard S., additional, Bhar, Paul, additional, Reddy, Sandeep K., additional, and Soon-Shiong, Patrick, additional

Published
2022
Full Text
View/download PDF

39. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

Author

Miller, Jeffrey S., primary, Davis, Zachary B., additional, Helgeson, Erika, additional, Reilly, Cavan, additional, Thorkelson, Ann, additional, Anderson, Jodi, additional, Lima, Noemia S., additional, Jorstad, Siri, additional, Hart, Geoffrey T., additional, Lee, John H., additional, Safrit, Jeffrey T., additional, Wong, Hing, additional, Cooley, Sarah, additional, Gharu, Lavina, additional, Chung, Hyunsoo, additional, Soon-Shiong, Patrick, additional, Dobrowolski, Curtis, additional, Fletcher, Courtney V., additional, Karn, Jonathan, additional, Douek, Daniel C., additional, and Schacker, Timothy W., additional

Published
2022
Full Text
View/download PDF

40. Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells

Author

Van der Meer, J. M. R., primary, Maas, R. J. A., additional, Guldevall, K., additional, Klarenaar, K., additional, De Jonge, P. K. J. D., additional, Hoogstad-van Evert, J. S., additional, van der Waart, A. B., additional, Cany, J., additional, Safrit, J. T., additional, Lee, J. H., additional, Wagena, E., additional, Friedl, P., additional, Önfelt, B., additional, Massuger, L. F., additional, Schaap, N. P. M., additional, Jansen, J. H., additional, Hobo, W., additional, and Dolstra, H., additional

Published
2021
Full Text
View/download PDF

44. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice

Author

Chu, Yaya, primary, Nayyar, Gaurav, additional, Jiang, Susiyan, additional, Rosenblum, Jeremy M., additional, Soon-Shiong, Patrick, additional, Safrit, Jeffrey T, additional, Lee, Dean A., additional, and Cairo, Mitchell S., additional

Published
2021
Full Text
View/download PDF

45. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Author

Foltz, Jennifer A., primary, Hess, Brian T., additional, Bachanova, Veronika, additional, Bartlett, Nancy L., additional, Berrien-Elliott, Melissa M., additional, McClain, Ethan, additional, Becker-Hapak, Michelle, additional, Foster, Mark, additional, Schappe, Timothy, additional, Kahl, Brad, additional, Mehta-Shah, Neha, additional, Cashen, Amanda F., additional, Marin, Nancy D., additional, McDaniels, Kristen, additional, Moreno, Chaz, additional, Mosior, Matthew, additional, Gao, Feng, additional, Griffith, Obi L., additional, Griffith, Malachi, additional, Wagner, Julia A., additional, Epperla, Narendranath, additional, Rock, Amy D., additional, Lee, John, additional, Petti, Allegra A., additional, Soon-Shiong, Patrick, additional, and Fehniger, Todd A., additional

Published
2021
Full Text
View/download PDF

48. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

Author

Van der Meer, J. M. R., primary, Maas, R. J. A., additional, Guldevall, K., additional, Klarenaar, K., additional, de Jonge, P. K. J. D., additional, Evert, J. S. Hoogstad-van, additional, van der Waart, A. B., additional, Cany, J., additional, Safrit, J. T., additional, Lee, J. H., additional, Wagena, E., additional, Friedl, P., additional, Önfelt, B., additional, Massuger, L. F., additional, Schaap, N. P. M., additional, Jansen, J. H., additional, Hobo, W., additional, and Dolstra, H., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results